Arjan van Manen joins BioLizard as Commercial Director, bringing over 20 years of commercial leadership experience in life ...

According to the paper by researchers at the University of Bath in the UK and Lund University in Sweden, the self-regulated ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Looking for broad exposure to the Large Cap Blend segment of the US equity market? You should consider the SPDR Russell 1000 Low Volatility Focus ETF (ONEV), a passively managed exchange traded fund ...

Like a champion boxer on the ropes, Bristol-Myers Squibb (NYSE: BMY) finds itself in a challenging position. Specifically, ...

The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and ...

Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...

Dr. Lubor Gaal joins MitoRx on a part-time basis, bringing over 25 years of global experience in business development, licensing, and strategic partnerships within the pharmaceutical and biotechnology ...

Researchers assessed the association of KRAS mutations in metastatic PDAC with the clinical outcomes and responses to first-line chemotherapy regimens.

International Assets Investment Management LLC cut its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 98.4% ...

A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, ...